Trial Profile

A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients With Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acimtamig (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms REDIRECT
Sponsors Affimed Therapeutics

16 Feb 2024 This trial has been Discontinued in Poland, According to European Clinical Trials Database.
31 Jan 2024 Status changed from active, no longer recruiting to completed.
15 Jun 2023 Results of post-hoc analysis assessing AFM13 efficacy based on a comprehensive list of characteristics; subgroups where meaningful differences in AFM13 response, presented at the 28th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com